

Special Issue

Recent Advances in Pulmonary Drug Delivery Systems

Message from the Guest Editors

In recent years, pulmonary drug delivery systems have become a method of drug delivery that has attracted much attention. PDDSs refer to a special dosage form that is administered with a special device, such that a drug acts on the lungs and exerts local or systemic effects through the deep part of the respiratory tract. Pulmonary drug delivery systems have the advantages of being non-invasive, a quick onset, fewer local metabolic enzymes, and localized drug delivery, and are widely used in the treatment of respiratory diseases. This Special Issue aims to collect the latest advances and state-of-the-art developments in the field of pulmonary drug delivery systems, including (but are not limited to) advanced drug delivery platforms for the treatment of respiratory diseases, in vitro/in silico/in vivo studies on the pulmonary drug delivery process and pulmonary deposition, the design of novel inhaler devices, studies relevant to potential lung toxicity and adverse effects of the excipients, and advanced delivery approaches for biopharmaceuticals. Original research and review papers that reflect this topic's status quo are warmly welcomed.

Guest Editors

Prof. Dr. Chuanbin Wu

Dr. Xuejuan Zhang

Dr. Sha Li

Deadline for manuscript submissions

closed (20 January 2025)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/177494

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).